Developers Voice Concern Over Draft Orphan Drug Loophole Guidance

FDA guidance that proposes to close what the agency sees as a “loophole” allowing drug developers to bypass pediatric study requirements would negatively impact child drug development if it becomes final, according to some drug developers and patient advocacy groups.
Source: International Pharmaceutical Regulatory Monitor